Humana Inc.(HUM)- NYSE
  • Nov. 5, 2015, 5:30 PM
  • Oct. 29, 2015, 5:52 PM
    • Humana (NYSE:HUM) declares $0.29/share quarterly dividend, in line with previous.
    • Forward yield 0.64%
    • Payable Jan. 29; for shareholders of record Dec. 30; ex-div Dec. 28.
    | Oct. 29, 2015, 5:52 PM
  • Oct. 19, 2015, 4:52 PM
    | Oct. 19, 2015, 4:52 PM
  • Oct. 19, 2015, 3:05 AM
    • Shareholders will get their say this week on two proposed health insurer mergers: Aetna's (NYSE:AET) $37B offer for Humana (NYSE:HUM), and Centene's (NYSE:CNC) $6.3B bid for Health Net (NYSE:HNT).
    • Although consumer advocates have raised concerns about whether the combination will lead to less competition and higher prices, proxy advisors ISS and Glass Lewis have given both deals a thumbs-up.
    • Aetna and Humana investors are scheduled to vote this afternoon and Centene and Health Net shareholders will cast their ballots on Friday.
    | Oct. 19, 2015, 3:05 AM
  • Oct. 13, 2015, 7:26 AM
    • Humana (NYSE:HUM) says its non-GAAP EPS guidance for Q3 and 2015 will remain at $2.15 and $7.75, respectively, despite incorporating adjustments for expenses related to the Aetna (NYSE:AET) transaction.
    • Its full-year guidance excludes a ~$267M pretax gain ($1.53 per share) from its sale of Concentra that was recognized in H1. Non-GAAP EPS for both Q4 and 2015 exclude transaction-related costs of ~$17M pretax ($0.10 per share) and $11M pretax ($0.07 per share), respectively.
    • The company will report Q3 results later this month.
    | Oct. 13, 2015, 7:26 AM | 1 Comment
  • Sep. 2, 2015, 1:29 PM
    • Forbes Contributor Bruce Japsen reports that the American Hospital Association (AHA) is urging the U.S. Justice Department to closely scrutinize Aetna's (AET +1.1%) proposed $37B takeout of Humana (HUM +0.4%). The hospital lobby says the deal would give Aetna too much power to raise prices of Medicare Advantage plans, the privately run portion of the Medicare program that has seen spectacular growth over the past few years.
    • Humana is the second largest insurer of Medicare Advantage while Aetna is the fourth largest. Almost one third of Medicare beneficiaries (~17M Americans) participate in Medicare Advantage.
    • AHA SVP and General Counsel Melinda Hatton says, "The deal will not just eliminate current competition between Humana and Aetna, it will eliminate future competition between them. It may create monopsony and enable the merged firm to exploit small, relatively powerless providers. Second, the merger may create downstream market power which could offset the desirable effects of countervailing power and premiums to consumers. Finally, the merger might create countervailing power but the merged firm might exercise it in anti-competitive ways, harming consumers or small providers."
    • It's doubtful, though, that the AHA's posturing will scupper the deal.
    | Sep. 2, 2015, 1:29 PM | 6 Comments
  • Aug. 27, 2015, 2:39 PM
    • Humana (NYSE:HUM) declares $0.29/share quarterly dividend, in line with previous.
    • Forward yield 0.63%
    • Payable Oct. 30; for shareholders of record Sept. 30; ex-div Sept. 28.
    | Aug. 27, 2015, 2:39 PM
  • Jul. 30, 2015, 1:37 PM
    • Unsurprisingly, Express Scripts (ESRX -0.6%) takes a dim view of the proposed price of the cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab). Last Friday, co-developers Sanofi (SNY +1.6%) and Regeneron Pharmaceuticals (REGN +0.4%) announced that the wholesale acquisition cost (WAC) of the once-every-two-week injection will be $40 per day or $14,600 per year. This is several orders of magnitude above the cost of statins, which average $2 - 3 per day.
    • WAC is the average price that wholesalers and distributors pay for the drug. Patients will, of course, pay quite a bit more.
    • Pharmacy benefit managers, still feeling the pinch from Gilead's (GILD +1.8%) HCV meds Sovaldi and Harvoni, will likely ratchet up their opposition as Praluent's U.S. launch commences.
    • Related tickers: (AET +0.9%)(CTRX)(CNC +0.9%)(CI -0.7%)(HUM)(MRK +0.3%)(OCR +0.4%)(UNH -0.7%)(CVS -0.5%)
    | Jul. 30, 2015, 1:37 PM | 126 Comments
  • Jul. 29, 2015, 8:36 AM
    • Humana (NYSE:HUM) Q2 results ($M): Total Revenues: 13,732 (+12.4%); Premiums: 13,212 (+14.1%); Services: 407 (-25.5%).
    • Net Income: 431 (+25.3%); EPS: 2.85 (+30.1%); CF Ops: (608) (+204%).
    • Benefit Expense Ratio: 87.1% (+2.2%); Total Medical Membership: 14,188.1 (0%).
    • Generic Dispense Rate: 89.2% (+1.0%); Script Volume: 194.5M (+21.4%).
    • 2015 Guidance: EPS: ~$9.28; Non-GAAP EPS: $7.75.
    • Q3 Guidance: EPS: ~$2.15.
    | Jul. 29, 2015, 8:36 AM
  • Jul. 29, 2015, 7:32 AM
    • Humana (NYSE:HUM): Q2 EPS of $1.67 beats by $0.04.
    • Revenue of $13.73B (+12.4% Y/Y) misses by $80M.
    | Jul. 29, 2015, 7:32 AM
  • Jul. 28, 2015, 5:30 PM
  • Jul. 24, 2015, 6:15 AM
    • Anthem (NYSE:ANTM) has agreed to buy Cigna (NYSE:CI) in a deal valued at $54.2B, wrapping up a year of negotiations and creating the largest health insurer in the U.S.
    • Cigna shareholders will get $103.40 per share in cash and 0.5152 Anthem shares.
    • The deal comes three weeks after Aetna (NYSE:AET) struck a deal to buy Humana (NYSE:HUM) for $37B and is part of an industry-wide consolidation following the roll-out of Obamacare.
    | Jul. 24, 2015, 6:15 AM | 14 Comments
  • Jul. 10, 2015, 2:45 AM
    • Aetna (NYSE:AET) is lining up a $16.2B bridge loan to fund its acquisition of Humana (NYSE:HUM) - the first multibillion M&A loan of 2H15 and the second-largest acquisition bridge loan so far this year.
    • On July 3, Aetna said it would buy Humana for $37B in the insurance industry's largest-ever acquisition.
    • In the past two weeks, Anthem has also offered to buy Cigna to create the largest insurer in the country, toppling UnitedHealth.
    | Jul. 10, 2015, 2:45 AM | 4 Comments
  • Jul. 8, 2015, 6:19 AM
    • In a regulatory filing, Humana (NYSE:HUM) and Aetna (NYSE:AET) have disclosed the termination fees to be paid if their $37B merger fails.
    • Aetna would pay a termination fee of $1.69B, while Humana would pay $1.31B. Aetna is also required to pay Humana $1B if the deal is not closed by June 30, 2016.
    | Jul. 8, 2015, 6:19 AM
  • Jul. 7, 2015, 3:56 AM
    • Aetna (NYSE:AET) shares tumbled over 6% yesterday, after Humana (NYSE:HUM) (which recently agreed to be acquired by the former for $37B) prompted investor concerns by lowering its forecasts for the year.
    • Stating inpatient hospital admissions were not performing in line with what it had expected, the company slashed its anticipated 2015 operating profits by more than 8%.
    • "If you take the downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive," said Tareo Capital's Joel Emery.
    • Previously: Humana and Aetna to host conference call this am to discuss merger; Humana lowers 2015 EPS guidance (Jul. 06 2015)
    | Jul. 7, 2015, 3:56 AM | 1 Comment
  • Jul. 6, 2015, 12:21 PM
    • Aetna's (AET -5.7%) conference call this morning about its takeover of Humana (HUM +2.7%) apparently failed to excite investors. Shares are down on 4x higher volume.
    • The market may perceive some antitrust risk in the deal. Humana is trading at $192 despite Aetna's bid of $230.
    • Previously: Confirmed: Aetna to acquire Humana for $37B (July 3)
    | Jul. 6, 2015, 12:21 PM | 9 Comments
Company Description
Humana, Inc. is a health care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates its business through the following segments: Retail, Employer Group, and Health and... More
Sector: Healthcare
Industry: Health Care Plans
Country: United States